Combination immunotherapy compositions against cancer and methods
AssigneesGlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
InventorsJames Hodge, Jeffrey Schlom, Alex Franzusoff
Life of this patent
Estimating the term…
Abstract
Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
Claims46
A method to reduce tumor burden or inhibit tumor growth in an individual, comprising administering two immunotherapy compositions within a dosing period, the two immunotherapy compositions comprising:
- a) a first immunotherapy composition comprising a recombinant Ad5 adenovirus comprising a nucleic acid sequence encoding a CEA peptide;
- and
- b) a second immunotherapy composition comprising a CEA peptide and either a whole inactivated yeast or yeast lysate.
A method to induce a therapeutic immune response against CEA in an individual, comprising administering two immunotherapy compositions within a dosing period, the two immunotherapy compositions comprising:
- a) a first immunotherapy composition comprising a recombinant Ad5 adenovirus comprising a nucleic acid sequence encoding a CEA peptide;
- and
- b) a second immunotherapy composition comprising a CEA peptide and either a whole inactivated yeast or yeast lysate.
Dependencies are inferred from the claim text.